Valliant, John - McMaster University - Department of Chemistry & Chemical Biology

个人简介

Scientific Director and CEO Centre for Probe Development and Commercialization John Valliant, PhD, is Scientific Director and CEO of the Centre for Probe Development and Commercialization (CPDC), a non-profit corporation for which he was integral in establishing. CPDC is focused on bridging the gap between academia and industry, enabling the development and commercialization of promising imaging probes and associated technologies. The Centre employs more than 30 research scientists, production technologists, quality assurance specialists and regulatory affairs experts focused on discovering, developing and distributing the next generation of molecular imaging probes. CPDC also plays an important role in Ontario's health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals across the province. Dr. Valliant completed his PhD at McMaster University, followed by a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT). Returning to McMaster in 1999, he became an assistant professor and was promoted to associate professor in 2005.

研究领域

John is internationally recognized for his work in radiopharmaceutical chemistry, where his current research focuses on developing new radiolabeling methods and compound discovery strategies to create clinically relevant molecular imaging probes and therapeutic radiopharmaceuticals. In recognition of his work and the emergence of the CPDC, John was asked to give the plenary lecture at the 2009 Society of Nuclear Medicine meeting and was recently selected as one of Canada's 2009 Top 40 Under 40. A distinction that recognizes his exceptional work at CPDC and McMaster University to advance molecular probe technology, improve patient care and spur on economic growth. The award also acknowledges his commitment to education and training at McMaster and within the imaging industry. Dr. Valliant's contribution to training highly qualified professionals within his research program is significant with several graduates taking research roles in both academic and industry settings in Canada and abroad. Dr. Valliant who is a Professor in the department of Chemistry and Chemical Biology, has an exceptional track record of securing funding for basic and translational research particularly as part of collaborative grants. Most recently, in partnership with the Cross Cancer Institute, John led a successful grant application to create a major training grant to educate the next generation of radiopharmaceutical scientists in Canada. In addition, he helped secure funding for a prototype breast imaging camera which is being evaluated in Hamilton as part of a collaborative trial. Dr. Valliant has published more than 75 papers in refereed journals and conference proceedings, and has been invited to speak at scientific conferences and leading research centres the world over. He currently has six patents or patent applications under review.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

J.P. Dzandzi, D.R. Beckford Vera, J.F. Valliant, "A hybrid solution-solid-phase kit-type radioiodination and purification platform", Society of Nuclear Medicine Annual Meeting, British Columbia, Canada, June 11, 2013. A. Zlitni, A.R. Genady, J.F. Valliant, "The development and evaluation of a multimodality imaging probe for US, SPECT and optical imaging", Society of Nuclear Medicine Annual Meeting, British Columbia, Canada, June 11, 2013. S.M. Rathmann, A. Darwish, N. Janzen, J.F. Valliant, "Triazole Appending Agent - A Novel Synthon for the Development of Targeted Iodine Based Molecular Imaging Probes", Imaging Applications in Prostate Cancer, London, Canada, Poster, Nov 16, 2012. A. Zlitni, A.R. Genady, J.F. Valliant, "The Preparation and Evaluation of Targeted Multimodality Imaging Probes for Prostate Cancer", Imaging Applications in Prostate Cancer, London, Canada, Poster, Nov 16, 2012. Laura Banevicius, Afaf Genady, John Valliant, "Evaluation of a multi-purpose molecular imaging probe and therapeutic agent for detection and treatment of prostate cancer", Imaging Applications in Prostate Cancer, London, Canada, Poster, Nov 16, 2012. Aimen Zlitni, Afaf R. Genady, John F. Valliant, "Developing a Platform for The Use of Microbubbles for Molecular, Optical and Ultrasound", Imaging Network Ontario Symposium, Toronto, Canada, Feb 14, 2012. Patricia E. Edem, John F. Valliant, "Evaluation of Cathepsin B Targeted Molecular Imaging Agents For the Detection of Aggressive Breast Cancers", Imaging Network Ontario Symposium, Toronto, Canada Feb, 2012. D. Weaver, R. Simms, K. Stephenson, J.F. Valliant, "Droplet Microreactors: A New Platform for Radiopharmaceuticals", Society of Nuclear Medicine, San Antonio, USA, June, 2011. J.F. Valliant, "Overview of Imaging Modalities", Ontario Institute for Cancer Research, Breast Imaging Symposium, Toronto, Ontario, October 2010 A. Darwish, M. Cooke, J.F. Valliant, "Bis-Benzimidazole Containing Single Amino Acid Chelates (SAACQ-2B): A New Class of Tridentate Chelates for 99mTc Imaging Probes," International Symposium on Technetium and Other Radiometals in Chemistry and Medicine, Bressanone, Italy. September 2010 M. Cooke, J.F. Valliant, "Synthesis and Characterization of Metallocarborane-based 1-Hydroxy-1,1'-Alkylidene Bisphosphonates for Tumour Imaging and Therapy," International Symposium on Technetium and Other Radiometals in Chemistry and Medicine, Bressanone, Italy. September 2010 A. Toppino, T. J. Gullon, J.F. Valliant, "The Preparation of a Tc-labelled analogue of Phenylalanine for Labelling Peptides," International Symposium on Technetium and Other Radiometals in Chemistry and Medicine, Bressanone, Italy. September 2010 P. E. Edem, J. F. Valliant, "Technetium Labelled Cathepsin B Inhibitors as Molecular Imaging Agents," International Symposium on Technetium and Other Radiometals in Chemistry and Medicine, Bressanone, Italy. September 2010 J.F. Valliant, "Modern ligand design for targeted metallo-radiopharmaceuticals: from radiochemistry through pharmacokinetics optimization", International Symposium on Technetium and Other Radiometals in Chemistry and Medicine, Bressanone, Italy, September 2010 (invited lecture) J.F. Valliant, "Multi-Modal Molecular Imaging Probes in the Era of Multi-Modality Imaging: Opportunities, Challenges and Recent Developments", General Electric, UK Research Facility, London UK, July 2010 J. F. Valliant, "Advances in Organometallic Chemistry for the Preparation of Molecular Imaging and Therapy Agents", International Symposium on Bioorganometallic Chemistry (ISBOMC'10), Bochum, Germany, July 2010 (invited) M. Hu, J. F. Valliant, "The measurement of in vitro and in vivo expression of urokinase-type plasminogen activiator receptor (uPAR) in human breast cancer cells using 111In-anti-uPAR", The 57th Society of Nuclear Medicine meeting, Salt Lake City, Utah, USA, June 2010 K. A. Stephenson, J. A. Lemon, J. R. Forbes, J. F. Valliant, "Novel probes targeting urokinase plasminogen activator (uPA) for imaging metastatic potential", The 57th Society of Nuclear Medicine meeting, Salt Lake City, Utah, USA, June 2010 J. F. Valliant, "Multi-Modal Molecular Imaging Probes in the era of Multi- Modality Imaging: Opportunities, Challenges and Recent Developments", Kaplan Lecture, Harvard University, Boston, MA, USA, May 2010 (Award and invited lecture) K. A. Stephenson, R. W. Simms, P. W. Causey, J. F. Valliant, "Using microfluidic reactors to prepare technetium and fluorine-18 based probes", The 93rd Canadian Society for Chemistry Conference, Toronto, ON, Canada, May 2010